Pharmacoeconomic review report: Dolutegravir/Rilpivirine (Juluca) (ViiV healthcare ULC)
Dolutegravir/rilpivirine (DTG/RPV) (Juluca) is an oral single-tablet regimen indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV ribonucleic acid [RNA] < 50 copies/mL). It contains: dolutegravir, an integrase stand transfer inhibitor (INSTI); and rilpivi...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
CADTH
2018, June 2018
|
Edition: | Final |
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | Dolutegravir/rilpivirine (DTG/RPV) (Juluca) is an oral single-tablet regimen indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV ribonucleic acid [RNA] < 50 copies/mL). It contains: dolutegravir, an integrase stand transfer inhibitor (INSTI); and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). DTG/RPV is available as a fixed-dose combination (50 mg/25 mg) tablet and is taken once daily. At the manufacturer-submitted unit price of $34.87 per tablet, the annual cost of treatment is approximately $12,728 per patient. The manufacturer is seeking reimbursement in accordance with the Health Canada indication |
---|---|
Physical Description: | 1 PDF file (26 pages) illustrations |